Erudio Healtherudio.com
Clinical trial · no report yet · Phase 1
AURORAS-1 trial: what clinicians have said so far
A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors
- NCT06983743 ↗
- Recruiting
- Erasca, Inc.
- Focused size, estimated: 1–150 verified statements
We haven't built an HCP commentary report on AURORAS-1 yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on AURORAS-1 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 3 posts on X |
The trial
ClinicalTrials.gov- Official title
- A Phase 1 First-in-Human Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of ERAS-0015 Monotherapy and in Combination in Patients Advanced Solid Tumors
- Phase
- Phase 1
- Status
- Recruiting
- Conditions
- Metastatic Solid Tumors
- Interventions
- ERAS-0015; ERAS-0015 in combination
- Arms
- ERAS-0015 Monotherapy Dose Optimization. · Experimental
- ERAS-0015 Combination Dose Optimization · Experimental
- Enrollment
- 600 (estimated)
- Primary outcomes
- Dose Limiting Toxicities (DLT)
- Maximum tolerated dose (MTD)
- Recommended dose for expansion (RDE)
- Adverse Events
- Plasma concentration (Cmax)
- Time to achieve Cmax (Tmax)
- Area under the curve
- Half-life
- Sponsor
- Erasca, Inc. with Merck Sharp & Dohme LLC
- Start
- Jun 5, 2025
- Primary completion
- May 1, 2028 (estimated)
- Results posted
- No
- Registry record
- NCT06983743 · updated Nov 6, 2026